CogState Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,888.40
5,062.20
2,641.90
853.10
730.40
Depreciation, Depletion & Amortization
684.70
736.60
869.20
1,023.10
841.10
Other Funds
185.70
2,275.90
229.00
1,581.30
1,322.20
Funds from Operations
3,805.30
2,225.10
2,063.80
1,630.00
2,166.20
Changes in Working Capital
518.20
493.60
566.80
1,612.40
2,268.10
Net Operating Cash Flow
3,287.00
2,718.70
2,630.60
3,242.50
101.90
Capital Expenditures
818.80
1,055.00
1,630.00
1,460.40
3,698.00
Sale of Fixed Assets & Businesses
-
8.50
-
-
-
Net Investing Cash Flow
818.80
1,046.50
1,630.00
1,460.40
3,698.00
Net Financing Cash Flow
7,754.30
2,065.10
862.20
473.20
198.30
Net Change in Cash
3,734.10
1,629.60
1,974.10
2,255.20
3,601.70
Free Cash Flow
4,105.80
3,773.70
1,000.60
1,782.10
722.80
Deferred Taxes & Investment Tax Credit
787.30
175.40
1,676.30
121.30
733.20
Change in Capital Stock
7,754.30
2,065.10
862.20
473.20
198.30
Exchange Rate Effect
85.70
70.50
111.30
-
-

About CogState

View Profile
Address
255 Bourke Street
Melbourne Victoria (VIC) 3000
Australia
Employees -
Website http://www.cogstate.com
Updated 07/08/2019
Cogstate Ltd. is a global cognitive science company, delivering software and services to optimize the measurement of cognition in clinical trials, academic research, healthcare and brain injury. The company operates through the following segments: Clinical Trials, precision recruitment, healthcare and sport. The Clinical Trials segment includes products and services were sold to pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on humans.